Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin 287 once-weekly vs insulin glargine once-daily in Japanese type 1 diabetes
jRCT2080224524Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of human insulin in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Steady-state pharmacokinetics of insulin 287, Steady-state pharmacodynamics (glucose-lowering effect) of insulin 287 and 1 more. Started Jan 2019; status: completed.
02
Drugs
human insulin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on jRCT2080224524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224524.